- New Therapeutic Agent for Chronic Hepatitis C: Direct Acting Agent
-
Chae HB
- KMID: 2373305
- Korean J Gastroenterol.
- 2015 Jul;66(1):5-9.
- doi: 10.4166/kjg.2015.66.1.5
Peg-interferon and ribavirin has been the standard therapy of chronic hepatitis C for the past 15 years in Korea. However, the treatment paradigm is changing. Direct acting agents (DAAs) are... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
-
Kim JH, Han KH, Lee KS, Park YN, Ahn SH, Chon CY, Moon YM
- KMID: 1777167
- Yonsei Med J.
- 2006 Dec;47(6):793-798.
- doi: 10.3349/ymj.2006.47.6.793
Combination therapy with interferon alpha (IFN- alpha) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%.... -
- CITED
-
- Close
- SHARE
-
- Close
